UBS O'Connor’s LAVA Medtech Acquisition Corp. Class A Common Stock LVAC Stock Holding History

UBS O'Connor’s Portfolio LVAC Stock Details LVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-283,573	Closed	-$2.96M	–	714
2023 Q1	$2.96M	Buy	+283,573	New	+$2.94M	0.07%	203
2022 Q4	–	Sell	-286,348	Closed	-$2.88M	–	646
2022 Q3	$2.88M	Sell	286,348 -28,666	-9%	-$287K	0.03%	444
2022 Q2	$3.14M	Buy	+315,014	New	+$3.15M	0.03%	447

UBS O'Connor's LVAC Position: Q2 2023 in Review

UBS O'Connor sold out of LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) in Q2 2023, closing a stake of 283,573 shares — an estimated $2.96M sold.

UBS O'Connor first reported a position in LVAC in Q2 2022 and held it in 3 quarters. The position peaked at $3.14M in Q2 2022. 0 funds tracked by Wall St. Rank hold LVAC as of Q2 2023.

UBS O'Connor reported no remaining LAVA Medtech Acquisition Corp. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
UBS O'Connor sold 283,573 LAVA Medtech Acquisition Corp. Class A Common Stock shares in Q2 2023, an estimated $2.96M.
UBS O'Connor first reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock in Q2 2022 and held it in 3 quarters.
UBS O'Connor's LAVA Medtech Acquisition Corp. Class A Common Stock position peaked at $3.14M in Q2 2022.
0 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Class A Common Stock as of Q2 2023.

Based on UBS O'Connor's 13F filing for Q2 2023, filed 14 Aug 2023.